OphthoSpecialty appeals · Ophthalmology

Ophthalmology denials: appealing anti-VEGF step-therapy denials

The ophthalmology denial worth appealing is usually the anti-VEGF one: the plan wants the cheaper agent tried first. Document the clinical reason for the specific drug and it's a winnable step-therapy fight — separate from the coding denials that fill the rest of the specialty.

The most appealable ophthalmology denials gate anti-VEGF injections (aflibercept, ranibizumab, faricimab) behind a step-therapy trial of bevacizumab for conditions like wet AMD, diabetic macular edema, and retinal vein occlusion. The appeal documents the trial, failure, or contraindication of the preferred agent and the clinical rationale for the specific drug, mapped to AAO Preferred Practice Patterns. Many other ophthalmology denials are coding or bundling issues, which are corrected rather than appealed.

Why these denials happen

Plans require a documented trial of bevacizumab before a brand anti-VEGF agent for the retinal indication, supported by imaging (such as OCT) and the diagnosis. AAO Preferred Practice Patterns support escalation when the preferred agent fails or isn't appropriate. The denial is usually a step-therapy documentation gap — the bevacizumab trail or the clinical reason for the specific agent isn't mapped to the plan's criteria.

The common denials

  • Anti-VEGF (aflibercept, ranibizumab, faricimab) denied for step therapy — bevacizumab trial not documented.
  • Imaging (OCT) or the diagnosis not established to the policy.
  • Clinical rationale for the specific brand agent over the preferred drug not documented.
  • Frequency or reauthorization criteria for ongoing injections not met.
  • Coding or bundling edits (a separate, correctable issue — not a medical-necessity appeal).

Is it worth appealing?

Sometimes worth appealing

Worth appealing the anti-VEGF step-therapy denials when the record supports the specific agent: the bevacizumab trial, failure, or contraindication, the imaging, and the clinical rationale, mapped to the plan's criteria and AAO Preferred Practice Patterns. A documented contraindication counts as a met step. Separate these from the coding and bundling denials common in ophthalmology, which are corrected rather than appealed.

How to appeal

  1. 1

    Document the bevacizumab step

    Show the trial, failure, intolerance, or contraindication of bevacizumab the plan requires — or the documented clinical reason the specific agent is needed first.

  2. 2

    Attach the imaging and diagnosis

    Include the OCT and the retinal diagnosis that establish the indication, mapped to AAO Preferred Practice Patterns.

  3. 3

    Separate coding from medical necessity

    If the denial is a modifier or bundling edit, correct the claim rather than running a clinical appeal.

Frequently asked

The plan wants Avastin (bevacizumab) before Eylea — can I appeal?
Yes, it's a step-therapy denial. Document the bevacizumab trial, failure, or contraindication and the clinical rationale for the specific agent, mapped to the plan's criteria and the AAO Preferred Practice Pattern.
Are most ophthalmology denials appealable?
Many are coding or bundling issues, which are corrected rather than appealed. The clearly appealable group is the anti-VEGF step-therapy and medical-necessity denials — separate those before drafting.

Related guides

CO-50 · medical necessityCO-197 · auth absentMedical-necessity letter

Sources

Clinical-coverage patterns and guideline references are summarized for plain-language reference and vary by plan and payer policy. This is general information for clinicians and billing staff, not medical, legal, or coding advice — confirm against the governing coverage policy and the current guideline for each claim.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →